Header Logo

Connection

JENNIFER FOSTER to Child

Back to Details
This is a "connection" page, showing publications JENNIFER FOSTER has written about Child.
JENNIFER FOSTER
Connection Strength
1.124
Child
  1. Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors. Pediatr Blood Cancer. 2026 May; 73(5):e70199.
    View in: PubMed
    Score: 0.057
  2. The impact of congenital heart disease on treatment and survival of patients with hepatoblastoma: A single-center experience. Pediatr Blood Cancer. 2024 Nov; 71(11):e31214.
    View in: PubMed
    Score: 0.051
  3. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
    View in: PubMed
    Score: 0.051
  4. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024 Jan; 71(1):e30732.
    View in: PubMed
    Score: 0.048
  5. Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
    View in: PubMed
    Score: 0.043
  6. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr Blood Cancer. 2021 07; 68(7):e29056.
    View in: PubMed
    Score: 0.040
  7. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
    View in: PubMed
    Score: 0.040
  8. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. Pediatr Blood Cancer. 2021 03; 68(3):e28871.
    View in: PubMed
    Score: 0.039
  9. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
    View in: PubMed
    Score: 0.039
  10. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
    View in: PubMed
    Score: 0.038
  11. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatr Blood Cancer. 2020 09; 67(9):e28334.
    View in: PubMed
    Score: 0.038
  12. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 04; 67(4):e28123.
    View in: PubMed
    Score: 0.037
  13. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Opin Drug Saf. 2018 Dec; 17(12):1257-1262.
    View in: PubMed
    Score: 0.034
  14. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.
    View in: PubMed
    Score: 0.034
  15. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer. 2018 12; 65(12):e27348.
    View in: PubMed
    Score: 0.034
  16. Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant. Pediatr Transplant. 2018 05; 22(3):e13141.
    View in: PubMed
    Score: 0.032
  17. Dinutuximab for the treatment of pediatric patients with neuroblastoma. Drugs Today (Barc). 2017 Sep; 53(9):469-476.
    View in: PubMed
    Score: 0.031
  18. Generic and Biosimilar Prescribing in Children and Adolescents: Policy Statement. Pediatrics. 2026 Jun 01; 157(6).
    View in: PubMed
    Score: 0.029
  19. Generic and Biosimilar Prescribing in Children and Adolescents: Technical Report. Pediatrics. 2026 Jun 01; 157(6).
    View in: PubMed
    Score: 0.029
  20. Essential Knowledge and Skills for the Practice of Pediatric Surgical Oncology: A Modified Delphi Consensus Study by the APSA Cancer Committee. Ann Surg Oncol. 2025 Aug; 32(8):5752-5771.
    View in: PubMed
    Score: 0.027
  21. Off-label use of drugs in children. Pediatrics. 2014 Mar; 133(3):563-7.
    View in: PubMed
    Score: 0.025
  22. Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer. 2011 Jul 15; 57(1):163-5.
    View in: PubMed
    Score: 0.020
  23. Drugs Used to Treat Pediatric Emergencies. Pediatrics. 2020 01; 145(1).
    View in: PubMed
    Score: 0.018
  24. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
    View in: PubMed
    Score: 0.014
  25. A Quality Improvement Initiative: Increasing Awareness of Long-Term Follow-Up Care in Pediatric Cancer Survivors and Caregivers. J Pediatr Hematol Oncol. 2026 Mar 01; 48(2):e84-e90.
    View in: PubMed
    Score: 0.014
  26. Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study. Transplant Cell Ther. 2026 Feb; 32(2):199.e1-199.e12.
    View in: PubMed
    Score: 0.014
  27. Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
    View in: PubMed
    Score: 0.013
  28. Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Glob Oncol. 2025 Mar; 11:e2400450.
    View in: PubMed
    Score: 0.013
  29. Real-World Experience Using Sodium Thiosulfate Pentahydrate Off-Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults. Pediatr Blood Cancer. 2025 May; 72(5):e31631.
    View in: PubMed
    Score: 0.013
  30. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
    View in: PubMed
    Score: 0.013
  31. Indications and Outcomes for Tracheostomies in Pediatric Oncology Patients-A Single Center Study. Pediatr Blood Cancer. 2025 Feb; 72(2):e31451.
    View in: PubMed
    Score: 0.013
  32. Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001-2020. Cancer Epidemiol. 2024 Oct; 92:102610.
    View in: PubMed
    Score: 0.013
  33. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516.
    View in: PubMed
    Score: 0.011
  34. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
    View in: PubMed
    Score: 0.011
  35. Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy. Pediatr Blood Cancer. 2023 01; 70(1):e29981.
    View in: PubMed
    Score: 0.011
  36. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022 10; 69(10):e29763.
    View in: PubMed
    Score: 0.011
  37. Associations of demographic and perinatal factors with childhood neuroblastoma in Texas, 1995-2011. Cancer Epidemiol. 2022 06; 78:102165.
    View in: PubMed
    Score: 0.011
  38. Preventing Home Medication Administration Errors. Pediatrics. 2021 12 01; 148(6).
    View in: PubMed
    Score: 0.011
  39. Thoracoscopic Resection of Thoracic Inlet Neuroblastic Tumors in Young Children. J Laparoendosc Adv Surg Tech A. 2021 Dec; 31(12):1475-1479.
    View in: PubMed
    Score: 0.010
  40. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021 Oct 01; 7(10):1550-1558.
    View in: PubMed
    Score: 0.010
  41. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
    View in: PubMed
    Score: 0.010
  42. Characteristics of benign neuroblastic tumors: Is surgery always necessary? J Pediatr Surg. 2022 Aug; 57(8):1538-1543.
    View in: PubMed
    Score: 0.010
  43. Role of anticoagulation in the management of tumor thrombus: A 10-year single-center experience. Pediatr Blood Cancer. 2021 09; 68(9):e29173.
    View in: PubMed
    Score: 0.010
  44. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021.
    View in: PubMed
    Score: 0.010
  45. Severe COVID-19 infection in a child receiving immunotherapy for cancer. Pediatr Blood Cancer. 2021 03; 68(3):e28710.
    View in: PubMed
    Score: 0.010
  46. Blood product administration during high risk neuroblastoma therapy. Pediatr Hematol Oncol. 2020 Feb; 37(1):5-14.
    View in: PubMed
    Score: 0.009
  47. A case series of pediatric oncology patients undergoing successful rapid etoposide desensitization. Pediatr Allergy Immunol. 2019 08; 30(5):579-582.
    View in: PubMed
    Score: 0.009
  48. Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019 08; 66(8):e27786.
    View in: PubMed
    Score: 0.009
  49. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov; 53(11):2235-2239.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.